-
Reata Pharmaceuticals – Omaveloxolone Update #5
Reata Pharmaceuticals has given an update on their clinical development programs, including their initiation of rolling submission of NDA for Omaveloxolone for treatment for patients with Friedreich’s Ataxia.
Read the press release and more information here.
The presentation provides an update on the company’s progress in submitting the NDA and what the company is doing to prepare for the commercial space. It also contains a review of the study results on FA and Omaveloxolone.
What are your thoughts?
Log in to reply.